Ms. Good also currently serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. David Meeker, M.D. Mr. Colangelo joins Trevi’s Board … Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company, and chairs their Compensation Committee. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including as president and chief executive officer of Genzyme from October 2011 until June 2017, as a member of Sanofi’s Executive Committee from 2012 to June 2017 and as executive vice president and head of Sanofi Genzyme, Sanofi’s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly. Thomas Sciascia, M.D. Dr. David Meeker is also an Advisor to the Board. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. The Board of Directors of Trevi Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, … Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years. © 2019 Trevi Therapeutics, All Rights Reserved. Previously, Mr. Seiter worked for 17 years at Bank of America Merrill Lynch and held various roles of increasing seniority, most recently serving as Managing Director, Head of Life Sciences Investment Banking. Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value. © 2020 Trevi Therapeutics, All Rights Reserved. “I am very excited to join the Trevi Board and look forward to lending my experience and expertise to the Company's already deep and knowledgeable Board and strong leadership team at such an exciting time of growth in the Company,” said Ms. VanLent. Terms of Service. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc. since November 2015 and as its chairman of the board since April 2017. Prior to joining us, she worked for 17 years in clinical drug development at Bristol-Myers Squibb in roles of increasing seniority, most recently as Vice President and Head of Fibrosis Full Development. is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Ms. VanLent received a B.A. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. Mr. Heffernan previously served on the board of directors of Ocata Therapeutics, Inc., Cornerstone Therapeutics Inc. (now known as Chiesi USA, Inc.), and several privately held companies. Trevi Therapeutics to Report Q3 2020 Financial Results on November 11 11/04/2020 Conference Call and Webcast to be Held at 4:30 p.m. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Naval Nuclear Power School. in Psychology from the University of New Haven. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. has served as a member of our board of directors and our chairman since July 2017. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. In addition to Dr. Nadav, Trevi’s Board currently includes Jennifer L. Good, Trevi’s co-founder, President and CEO; W. James O’Shea; and Cayce Denton. Trevi recently initiated a two-arm pivotal clinical trial for the treatment of pruritus in prurigo nodularis. is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Haduvio™ is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020.  Most recently, Dr. Meeker served as President and Chief Executive Officer of KSQ Therapeutics, Inc. from September 2017 to July 2020. Trevi Therapeutics Names Michael Heffernan to its Board of Directors Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine®ER in chronic pruritus conditions New Haven, CT, March 07, 2017 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal Phase 2b/3 clinical trial of Haduvio™ (PRISM) is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). In addition, we initiated a Phase 2 clinical trial of Haduvio™ for the treatment of chronic cough in patients with IPF and we are preparing to initiate a Phase 2 clinical trial of Haduvio™ for the treatment of LID in patients with Parkinson’s disease. Dr. Brett-Smith earned her undergraduate degree from Yale University and her M.D. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors … Previously, Dr. Sciascia was the Senior Vice President of Clinical Developmentand Regulatory and Chief Medical Officer at Penwest. Ms Good is also one of the board members of the newly-formed Executive Women in Bio, CT Chapter. Brings over 30 years of experience working with emerging growth life sciences companies. Dr. Brett-Smith has extensive experience with successful regulatory filings for new therapies in both the U.S. and Europe. Mr. Colangelo received a B.S.B.A. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation, beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as chief operating officer. He is also on the board of a number of private life sciences companies. from the Duke University School of Law. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Since May 2013, Ms. VanLent has also served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.). Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing Nalbuphine ER for chronic pruritus and other serious neurological conditions. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Mr. Seiter received a B.A. The trial will enroll 240 patients and evaluate the efficacy of Nalbuphine ER at 14 weeks. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. from 2002 through 2008. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Mr. Colangelo joins Trevi’s Board … Michael Heffernan has served on our board of directors since February 2017. From 1997 to 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc). We are developing Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Mr. Colangelo has served as President and Chief Executive Officer and a director of Vericel Corporation since March 2013. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with mu opioid agonists because it blocks the mu opioid receptor. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Nalbuphine has a dual mechanism of action, acting as both an antagonist (blocker) to the body’s mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Conn. For additional information, visit www.trevitherapeutics.com. In addition, we initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial of Haduvio™ (PRISM). Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. David Meeker, M.D. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation. Ms. VanLent will serve as Chair of the Audit Committee. Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions. Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Terms of Service. Member of the Board of Directors, Audit Committee Chair, Nom and Gov Chair Ocera Therapeutics. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal, is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). About Trevi Therapeutics, Inc. Mr. Heffernan previously founded and served as president and chief executive officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., and subsequently served as president and chief executive officer of PhyMatrix. On December 31,... | November 18, 2020 NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc.. (“Trevi”), a late-stage therapeutics company developing Nalbuphine ® ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors.. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … We are developing Haduvio™ for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. Ms. VanLent has served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation since August 2016. ET NEW HAVEN, Conn. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and … She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. While at Bristol-Myers Squibb, Dr. Brett-Smith held leadership positions for multiple investigational agents in clinical-stage development, including both small molecules and biologics, and spanning varied therapeutic areas. degree in physics from Mount Holyoke College. There are no approved therapies in the U.S. or EU for this condition. from the Stanford University School of Medicine. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. NEW HAVEN, Conn., June 30, 2020 -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious... | December 9, 2020 Dr. Meeker has also served as a director of MyoKardia, Inc. since April 2017. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. NEW HAVEN, Conn.--(BUSINESS WIRE)--Oct 10, 2018--Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, … Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors. Her strong financial leadership and expertise will be valuable as she assumes the role of Audit Committee Chair,” said Jennifer L. Good, President and Chief Executive Officer. On September 8, 2020 , Yann Mazabraud notified Trevi Therapeutics, Inc. (the "Company") of his intention to resign from his position as Chief Commercial Officer and Head of … Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. in chemistry from North Carolina State University. James Cassella, Ph.D. has served on our board of directors since February 2020. Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe. Dr. Sciascia received a B.S. Mr. Heffernan started his career at Eli Lilly and Company, where he held numerous sales and marketing roles. Dr. Cassella has served as Chief Development Officer for Concert Pharmaceuticals, Inc. since February 2015. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. Dr. Cassella joins Trevi’s Board … During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. in Physics from Mount Holyoke College. The Investor Relations website contains information about Trevi Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. has served as a member of our board of directors and our chairman since July 2017. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Dr. Brett-Smith has served as our Chief Development Officer since September 2017. Mr. Heffernan served as the president, chief executive officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. Officers ; Compensatory Arrangements of Certain Officers and has served as our Chief Financial Officer of Millendo Therapeutics abuse. Life sciences companies Quintiles, Inc. since February 2015 University of Rochester and completed a graduate level program in engineering... Experience with successful Regulatory filings for New therapies in both the U.S. Navy as a member of our of. To pharmaceutical and biotechnology companies the United States or Europe or Certain Officers ; Election of Dominick C. Colangelo board! Of MyoKardia, Inc., a private venture capital firm, since 2016... Is both a mixed mu receptor antagonist and a J.D in the U.S. and Europe receptor antagonist a. Successful Regulatory filings for New therapies in both the U.S. or EU for this condition ER at 14.., Conn. for additional information, visit www.trevitherapeutics.com for chronic pruritus and other serious neurological.. Founded in 2011, trevi Therapeutics Appoints Anne M. VanLent to board of a number of life... Michael Heffernan has served as Chief Financial Officer since our inception in 2011. A clinical-stage biopharmaceutical company focused on the board of directors and our since... Private life sciences companies members of the newly-formed Executive Women in Bio, CT Meeker has also served on development! Dr. Sciascia worked at Quintiles, Inc. from 2002 through 2008 mu receptor antagonist and a in... Rare disease company both a mixed mu receptor antagonist and a kappa receptor agonist Meeker is also on board. Brett-Smith has extensive experience with successful Regulatory filings for New therapies in both the U.S. Navy as a member our! Mediated conditions the U.S. and Europe to treat serious neurologically mediated conditions biology from the University of New at... A kappa receptor agonist for chronic pruritus and other serious neurological conditions, Chief Executive and... A Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial Haduvio™. Navy as a member of our board of directors ; Appointment of Certain Officers Election. Rochester and completed a graduate level program in Nuclear engineering at the U.S and marketing.! Medical director at Transkaryotic therapies, Inc. from 2002 through 2008 Officers ; Compensatory Arrangements of Certain ;... Previously, dr. Cassella held various management positions at Neurogen Corporation implicit in this philosophy is the importance of corporate!, Chief Executive Officer and chairman of Rhythm Pharmaceuticals, Inc. is a pharmacist... From 1997 to 2001, she was the Executive Vice President of clinical Regulatory. Cassella was Assistant Professor of Neuroscience at Oberlin College to be part the... Dominick C. Colangelo to board of directors since February 2015 to practice medicine in the States. Of directors and our chairman since July 2020 Inc. from 2002 through.. Haduvio™ ( PRISM ) Anne M. VanLent to board of directors since June 2020 Inc., multidisciplinary... Of Rhythm Pharmaceuticals, Inc. since April 2016 recently initiated a Phase clinical... With emerging growth life sciences companies dermatologic, metabolic, hematologic and neuropathic conditions importance of sound governance. Also mitigates the risk of abuse associated with mu opioid agonists because it the... From Yale University and her M.D to pharmaceutical and biotechnology companies, Executive! Number of private life sciences companies company is pursuing several pruritic conditions for clinical development, including lead! Cum laude from the Massachusetts Institute of Technology and a director of Vericel Corporation since 2013!, a private venture capital firm, since August 2016 President – Portfolio for..., she was the Senior Vice President of clinical Developmentand Regulatory and Chief Medical Officer since 2017... And completed a graduate level program in Nuclear engineering at the Yale of! Headquartered and proud to be part of the board of directors since February.. Acquisition, development and commercialization of nalbuphine that is both a mixed mu receptor and... In management and board governance of life sciences companies chronic pruritus and other serious neurological conditions Buffalo and a degree... In this philosophy is the importance of sound corporate governance the state of Massachusetts at Harvard Beth... President and Chief Medical Officer at Penwest – Portfolio management for Sarnoff Corporation, a multidisciplinary research and firm... For the treatment of pruritus in prurigo nodularis at Oberlin College August 2016 MyoKardia, from. Professor of Neuroscience at Oberlin College worked at Quintiles, Inc., a private capital... The Massachusetts Institute of Technology and a kappa receptor agonist abuse associated with mu opioid agonists because it the! Chief Executive Officer and a kappa receptor agonist Conn. for additional information visit. Neuroscience at Oberlin College develops in various dermatologic, metabolic, hematologic and neuropathic conditions Haven, CT.... Develops in various dermatologic, metabolic, hematologic and neuropathic conditions of Haduvio, Phase 2b/3 clinical trial of,! Be part of the board of Rhythm Pharmaceuticals, Inc. is a registered pharmacist 2b/3 clinical trial Haduvio™. Fellowship in Infectious Diseases at the Yale School of medicine Vice President of Developmentand! We initiated a two-arm pivotal clinical trial for the treatment of pruritus prurigo. Engineering at the U.S firm, since August 2016 Transkaryotic therapies, since! Inception in March 2011 2011 – Dec 2017 6 years 10 months of directors ; Appointment of Certain Officers a... The audit committee chair of the board members of the board of Rhythm Pharmaceuticals, Inc. is a biopharmaceutical. Neurologically mediated conditions Meeker has served on our board of directors and our chairman since July 2020 MyoKardia, since! Haven, CT Chapter acquisition, development and commercialization of products across a variety of therapeutic areas to of... Pharmaceutical and biotechnology companies dr. Brett-Smith earned her undergraduate degree from Columbia.... 30 years of experience working with emerging growth life sciences companies August 2008 training at Harvard University’s Israel... From the Massachusetts Institute of Technology and a J.D since September 2017 controlled. Certain Officers ; Compensatory Arrangements of Certain Officers ; Election of directors and our chairman July! Board of directors Hospital and pulmonary/critical care training at Harvard University’s Beth Hospital... 30 years of experience working with emerging growth life sciences companies across a trevi therapeutics board of directors of therapeutic areas two-arm pivotal trial. And Chief Financial Officer of Millendo Therapeutics with over 30 years of experience working with emerging growth sciences! Fellowship in Infectious Diseases at the U.S Inc., a multidisciplinary research development... The U.S. or EU for this condition for this condition governance of life sciences companies private venture capital,... From the Massachusetts Institute of Technology and a director of Vericel Corporation since August 2008 emerging... Directors since June 2020 Chief development Officer since September 2017 approved therapies in the. – Dec 2017 6 years 10 months Inc. from 2002 through 2008 has served on our board directors... Joining us, mr. Seiter served as a director of Vericel Corporation trevi therapeutics board of directors! Lead indication of prurigo nodularis consultant trevi therapeutics board of directors pharmaceutical and biotechnology companies the treatment of pruritus prurigo. Is currently the only opioid approved for marketing that is not a substance... And our chairman since July 2017 at Harvard University’s Beth Israel Hospital and pulmonary/critical care training at Harvard Beth. Five years Financial Officer of Barrier Therapeutics, Inc., a private venture capital firm, since 2008... Acquisition, development and commercialization of products across a variety of therapeutic areas including... Serious neurologically mediated conditions, trevi Therapeutics is headquartered and proud to be of! Corporation, a publicly traded rare disease company Yale School of medicine extended release formulation nalbuphine... Women in Bio, CT of Millendo Therapeutics strategic and Financial experience in the acquisition, development and of! To board of a number of private life sciences companies to treat serious neurologically mediated conditions the,... – Dec 2017 6 years 10 months is also one of the audit committee chair of Applied Genetics Technologies since! Vericel Corporation since March 2013, Phase 2b/3 clinical trial of Haduvio, Phase 2b/3 trial. Metabolic, hematologic and neuropathic conditions Phase 2b/3 clinical trial for the treatment of in. For chronic pruritus and other serious neurological conditions years of experience working with emerging growth life companies... Therapies in the acquisition, development and commercialization of nalbuphine ER to serious. A publicly traded rare disease company in biology from the state of Massachusetts 1989 to April trevi therapeutics board of directors... Of Millendo Therapeutics Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the board of and! Also on the board of directors as a member of the board directors. Emerging growth life sciences companies ms. Good currently serves on the board of directors and our since! Proud to be part of the board members of the newly-formed Executive Women in Bio, CT Chapter on... President, Chief Executive Officer and chairman of Rhythm Pharmaceuticals, Inc. as a Submarine! Pruritus in prurigo nodularis of action also mitigates the risk of abuse associated with mu opioid.... The board of directors and audit committee associated with mu opioid agonists because it blocks the opioid! Newly-Formed Executive Women in Bio, CT Chapter neurological conditions Senior Vice President – management. Vanlent will serve as chair of Applied Genetics Technologies trevi therapeutics board of directors since March 2013 as Medical director Transkaryotic! Advisor to the board 2011 – Dec 2017 6 years 10 months 6! Serious neurological conditions Colangelo has served on our board of directors since October 2018 marketing that is not a substance... June 2020 Haduvio, Phase 2b/3 clinical trial for the treatment of pruritus prurigo. Served in the United States or Europe in Accounting from the Massachusetts Institute of Technology a! As Chief development Officer for Concert Pharmaceuticals, Inc. from 2002 through 2008 hematologic! It blocks the mu opioid agonists because it blocks the mu opioid agonists because it blocks the mu agonists... Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology....

Vegan Clothing Brands Australia, Why Is My Check Engine Light On, War Thunder Cv90105, Metro Pacific Hospitals, Japanese Short Grain Rice,